These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 33502260)
1. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Louis C; Edeline J; Coulouarn C Expert Opin Ther Targets; 2021 Feb; 25(2):153-162. PubMed ID: 33502260 [No Abstract] [Full Text] [Related]
2. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Wang J; Ilyas S Expert Opin Investig Drugs; 2021 Apr; 30(4):429-438. PubMed ID: 33322977 [No Abstract] [Full Text] [Related]
3. Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells? Wang J; Loeuillard E; Gores GJ; Ilyas SI Expert Opin Ther Targets; 2021 Oct; 25(10):835-845. PubMed ID: 34806500 [TBL] [Abstract][Full Text] [Related]
4. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies. Cao H; Huang T; Dai M; Kong X; Liu H; Zheng Z; Sun G; Sun G; Rong D; Jin Z; Tang W; Xia Y Int J Biol Sci; 2022; 18(14):5369-5390. PubMed ID: 36147461 [TBL] [Abstract][Full Text] [Related]
5. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications. Wu HJ; Chu PY Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450710 [TBL] [Abstract][Full Text] [Related]
6. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review). Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583 [TBL] [Abstract][Full Text] [Related]